ClinicalTrials.gg
RecruitingNCT06802718Updated Jan 31, 2025

Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

A Phase 3 interventional study of Interferon in Acute Myeloid Leukemia, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-31.

Sponsored by Peking University People's Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Jan 2023, registered Dec 2024).
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital — 15 open to participants now, 16 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · Peking University People's Hospital.

Planned enrollment
6th of 17
96 · median 52
Started
2023
with 4 others
Phase 3
2 of 20
2 open now
Primary completion
2026-12
later than 6 of 15 live
Registered
11th of 20
by date

Among the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2023, is one of 2 in phase 3, reaches primary completion later than 6 of the 15 other live ones, and was the 11th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

15 of the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital, or all of them as a file.
02

Study summary

This research focuses on a prospective, randomized, controlled trial of "Interferon-alpha as maintenance therapy for favorable-risk acute myeloid leukemia." By fully utilizing prospective, randomized, controlled clinical trial and studying the negative conversion of MRD and the survival of favorable-risk AML patients, it aims to explore the efficacy and safety of Interferon-alpha in the maintenance treatment of favorable-risk AML and identify effective measures to prevent relapse, thereby improving the survival of favorable-risk AML patients. The primary endpoint is the negative conversion of MRD at 6 months. The secondary endpoints include the 2-year cumulative incidence of relapse, 2-year event-free survival (EFS), 2-year overall survival (OS), and safety.

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-70 years old (including 18 and 70 years old) with newly diagnosed favorable-risk AML (2022 ELN risk group classification).
  • Achieved CR1 after 1-2 cycles of standard chemotherapy.
  • Completed 4-6 cycles of consolidation chemotherapy (including at least 2 cycles of high-dose Cytarabine HDAC regimem).
  • At the end of consolidation treatment, bone marrow examination confirmed in CR1, flow cytometry MRD negative, but molecular MRD genes (RUNX1:: RUNX1T1, NPM1, and CBFb:: MYH11) decreased by > 3 log, but still detectable.
  • Performance status score of 0-2 ().
  • Liver function: and AST ≤ 2.5 times the , ≤ 2 times the upper limit of normal.
  • Kidney function: Creatinine ≤ 1.5 times the upper limit of normal.

Exclusion criteria

Exclusion Criteria:

  • Acute promyelocytic leukemia (APL).
  • AML with normal karyotype and bZIP intramolecular mutations in CEBPA.
  • ≥ CR2 status.
  • Patients strongly demanding transplantation, and with indications for transplantation but not eligible for transplantation.
  • Uncontrolled active infection.
  • Severe organ dysfunction.
  • Pregnancy.
  • Unwillingness to undergo interferon treatment.
  • Previous hyperthyroidism or hypothyroidism.
  • Participation in other clinical trials within one month.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Interferon Group

    Polyethylene glycol interferon alpha-2b injection 135 μg/week was subcutaneously given for 6 months.

    Drug: Interferon

  • No intervention
    Control Group

    Observational follow-up without receiving any maintenance treatment.

Interventions

06

What researchers measure

Primary outcomes

  1. 6-month negative conversion of MRD

    MFC-MRD or RT-PCR genes (AML1-ETO, NPM1, and CBFb-MYH11) transition from positive to negative.

    Time frame: Participants will be followed for a minimum of 2 years until the last enrolled participants was followed up for at least 2 years.

Secondary outcomes

  1. CIR

    The number of patients with relapse calculated from the randomization time to the last follow-up time.

    Time frame: Participants will be followed for a minimum of 2 years until the last enrolled participants was followed up for at least 2 years.

  2. EFS

    Events include treatment failure (MRD positivity or molecular progression), relapse, or death from any cause.

    Time frame: Participants will be followed for a minimum of 2 years until the last enrolled participants was followed up for at least 2 years.

  3. OS

    calculated from randomization time to the time of death or the last follow-up time.

    Time frame: Participants will be followed for a minimum of 2 years until the last enrolled participants was followed up for at least 2 years.

  4. Treatment-related Safety Indicators

    Mainly include hematologic toxicity and liver toxicity.

    Time frame: Participants will be followed for a minimum of 2 years until the last enrolled participants was followed up for at least 2 years.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.

Of 78 non-industry phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 66 and three quarters within 111. This study's planned 47 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2024
First posted
Jan 31, 2025
StartActual
Jan 1, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06802718
Responsible party
Xiao-Jun Huang (Principal Investigator, Peking University People's Hospital) — Principal investigator
First posted
Jan 31, 2025
Start date
Jan 1, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 31, 2025

Study contacts

Feifei Tang, Prof
Contact
bjmugirl@163.com
13581671687

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferons

Start the discussion